Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) announced on Monday that it has successfully treated the first patient in its Phase I clinical trial of HG-CT-1, a proprietary CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML). The treatment was well tolerated with no adverse effects, passing initial safety assessments.

Early signs of efficacy are promising, with ongoing patient monitoring to evaluate secondary trial endpoints, including response rates, overall survival and progression-free survival. Manufacturing of HG-CT-1 is underway for a second patient.

The dose-escalation study aims to establish the safety profile of HG-CT-1 in adults with R/R AML, a population with limited treatment options. Data on efficacy and long-term clinical outcomes will be collected through continued follow-up.

Hemogenyx Pharmaceuticals, headquartered in London with research operations in New York, is developing novel therapies for blood and autoimmune diseases, focusing on expanding the accessibility of bone marrow transplantation. Further updates on the trial will follow in due course.